This Could Be the Ultimate ETF for Warren Buffett Fans
If you’re a fan of Warren Buffett and want to track the stocks in the Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) portfolio, then there’s one exchange-traded fund (ETF) that you may want to consider investing in. The VistaShares Target 15 Berkshire Select Income ETF (NYSE Arca:OMAH) launched earlier this year, and the fund gives investors exposure to Berkshire stock as well as to the top 20 holdings in Berkshire’s portfolio. Its primary goal is to generate income, followed by capital appreciation. The top three holdings in the ETF are Apple (NASDAQ:AAPL), Berkshire Hathaway, and American Express (NYSE:AXP). Those holdings combine for close to 29% of the fund’s overall weight. For Buffett fans, this can be the ultimate ETF to add to your portfolio. You don’t have to worry about keeping track of which stocks Berkshire is buying and selling. And you also get exposure to Berkshire stock as well, which has been doing well; it has risen by 20% over the past year. One unattractive feature about the fund, however, is that its expense ratio is fairly high at 0.95%. But with the fund’s goal being to achieve annual income of 15%, that may not be too bad. The fund is utilizing options to help generate high monthly income. And one feature that income investors will certainly like is that the fund’s distributions are made on a monthly basis. If you want some monthly income and love Buffett stocks, this could be a great ETF to add to your portfolio today and hang on to for the long haul.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


